Hypoparathyroidism News and Research

RSS
Shire announces availability of Natpara (parathyroid hormone) for injection in U.S.

Shire announces availability of Natpara (parathyroid hormone) for injection in U.S.

NPS Pharmaceuticals reports net global product sales of $15.3 million for Q4 2013

NPS Pharmaceuticals reports net global product sales of $15.3 million for Q4 2013

FDA accepts NPS Pharmaceuticals' Natpara BLA for review

FDA accepts NPS Pharmaceuticals' Natpara BLA for review

NPS Pharmaceuticals' Natpara gets orphan drug designation for treatment of hypoparathyroidism

NPS Pharmaceuticals' Natpara gets orphan drug designation for treatment of hypoparathyroidism

NPSP to conduct open-label study to evaluate teduglutide in pediatric patients with SBS

NPSP to conduct open-label study to evaluate teduglutide in pediatric patients with SBS

Recombinant hormone could REPLACE calcium supplements

Recombinant hormone could REPLACE calcium supplements

Four new pre-clinical drug development projects at NIH develop treatment for rare disease

Four new pre-clinical drug development projects at NIH develop treatment for rare disease

NPS Pharmaceuticals president receives Ernst & Young Entrepreneur Award in Life Sciences category

NPS Pharmaceuticals president receives Ernst & Young Entrepreneur Award in Life Sciences category

EC grants European market authorization for Revestive to treat short bowel syndrome

EC grants European market authorization for Revestive to treat short bowel syndrome

FDA committee to review NPS’ Gattex NDA in October

FDA committee to review NPS’ Gattex NDA in October

FDA extends PDUFA action date for NPS Gattex NDA

FDA extends PDUFA action date for NPS Gattex NDA

Investigational parathyroid hormone replacement effectively treats hypoparathyroidism

Investigational parathyroid hormone replacement effectively treats hypoparathyroidism

European CHMP adopts positive opinion for teduglutide to treat short bowel syndrome

European CHMP adopts positive opinion for teduglutide to treat short bowel syndrome

Gattex may represent new treatment approach for short bowel syndrome

Gattex may represent new treatment approach for short bowel syndrome

NPS first quarter net loss increases to $10.6 million

NPS first quarter net loss increases to $10.6 million

Positive top-line results from NPSP558 Phase 3 study on hypoparathyroidism

Positive top-line results from NPSP558 Phase 3 study on hypoparathyroidism

NPS announces new data from GATTEX Phase 3 study on short bowel syndrome

NPS announces new data from GATTEX Phase 3 study on short bowel syndrome

NPS announces data about hypoparathyroidism to be presented at ASBMR 2011 meeting

NPS announces data about hypoparathyroidism to be presented at ASBMR 2011 meeting

NPS submits NDA CMC section to FDA for GATTEX

NPS submits NDA CMC section to FDA for GATTEX

GSK, NPS enter agreement to evaluate ronacaleret in new indications

GSK, NPS enter agreement to evaluate ronacaleret in new indications